{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:46:10Z","timestamp":1792183570250,"version":"4.4.0"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T00:00:00Z","timestamp":1314662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1038\/nrendo.2011.142","type":"journal-article","created":{"date-parts":[[2011,8,30]],"date-time":"2011-08-30T13:45:27Z","timestamp":1314711927000},"page":"569-580","source":"Crossref","is-referenced-by-count":848,"title":["Molecular genetics and diagnosis of thyroid cancer"],"prefix":"10.1038","volume":"7","author":[{"given":"Yuri E.","family":"Nikiforov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina N.","family":"Nikiforova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,30]]},"reference":[{"key":"BFnrendo2011142_CR1","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs","author":"RA DeLellis","year":"2004","unstructured":"DeLellis, R. A., Lloyd, R. V., Heitz, P. U. & Eng, C. (Eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs (IARC Press, Lyon, 2004)."},{"key":"BFnrendo2011142_CR2","first-page":"94","volume-title":"Diagnostic Pathology and Molecular Genetics of the Thyroid","author":"YE Nikiforov","year":"2009","unstructured":"Nikiforov, Y. E. in Diagnostic Pathology and Molecular Genetics of the Thyroid (eds Nikiforov, Y. E., Biddinger, P. W. & Thompson, L. D. R.) 94\u2013102 (Lippincott Williams & Wilkins, Baltimore, 2009)."},{"key":"BFnrendo2011142_CR3","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1001\/jama.295.18.2164","volume":"295","author":"L Davies","year":"2006","unstructured":"Davies, L. & Welch, H. G. Increasing incidence of thyroid cancer in the United States, 1973\u20132002. JAMA 295, 2164\u20132167 (2006).","journal-title":"JAMA"},{"key":"BFnrendo2011142_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12022-007-0002-z","volume":"18","author":"J Albores-Saavedra","year":"2007","unstructured":"Albores-Saavedra, J., Henson, D. E., Glazer, E. & Schwartz, A. M. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype\u2013papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr. Pathol. 18, 1\u20137 (2007).","journal-title":"Endocr. Pathol."},{"key":"BFnrendo2011142_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/thy.2006.16.47","volume":"16","author":"JR Burgess","year":"2006","unstructured":"Burgess, J. R. & Tucker, P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16, 47\u201353 (2006).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR6","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ejca.2006.11.024","volume":"43","author":"M Colonna","year":"2007","unstructured":"Colonna, M. et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983\u20132000). Eur. J. Cancer 43, 891\u2013900 (2007).","journal-title":"Eur. J. Cancer"},{"key":"BFnrendo2011142_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0002-9343(92)90163-6","volume":"93","author":"EL Mazzaferri","year":"1992","unstructured":"Mazzaferri, E. L. Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am. J. Med. 93, 359\u2013362 (1992).","journal-title":"Am. J. Med."},{"key":"BFnrendo2011142_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4158\/EP.10.1.31","volume":"10","author":"H Gharib","year":"2004","unstructured":"Gharib, H. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr. Pract. 10, 31\u201339 (2004).","journal-title":"Endocr. Pract."},{"key":"BFnrendo2011142_CR9","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1210\/jc.2006-0690","volume":"91","author":"MC Frates","year":"2006","unstructured":"Frates, M. C. et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J. Clin. Endocrinol. Metab. 91, 3411\u20133417 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR10","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1210\/jcem.87.5.8504","volume":"87","author":"E Papini","year":"2002","unstructured":"Papini, E. et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J. Clin. Endocrinol. Metab. 87, 1941\u20131946 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/1097-0142(20001225)90:6<335::AID-CNCR3>3.0.CO;2-L","volume":"90","author":"TS Greaves","year":"2000","unstructured":"Greaves, T. S. et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer 90, 335\u2013341 (2000).","journal-title":"Cancer"},{"key":"BFnrendo2011142_CR12","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.amjsurg.2003.08.015","volume":"186","author":"GM Sclabas","year":"2003","unstructured":"Sclabas, G. M. et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am. J. Surg. 186, 702\u2013709 (2003).","journal-title":"Am. J. Surg."},{"key":"BFnrendo2011142_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/thy.2006.16.109","volume":"16","author":"DS Cooper","year":"2006","unstructured":"Cooper, D. S. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109\u2013142 (2006).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR14","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/cncr.23116","volume":"111","author":"L Yassa","year":"2007","unstructured":"Yassa, L. et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111, 508\u2013516 (2007).","journal-title":"Cancer"},{"key":"BFnrendo2011142_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.pas.0000176432.73455.1b","volume":"30","author":"AJ Adeniran","year":"2006","unstructured":"Adeniran, A. J. et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 30, 216\u2013222 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrendo2011142_CR16","first-page":"1454","volume":"63","author":"ET Kimura","year":"2003","unstructured":"Kimura, E. T. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET\/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63, 1454\u20131457 (2003).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR17","doi-asserted-by":"publisher","first-page":"4578","DOI":"10.1038\/sj.onc.1206706","volume":"22","author":"P Soares","year":"2003","unstructured":"Soares, P. et al. BRAF mutations and RET\/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22, 4578\u20134580 (2003).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR18","doi-asserted-by":"publisher","first-page":"7436","DOI":"10.1038\/sj.onc.1207980","volume":"23","author":"M Frattini","year":"2004","unstructured":"Frattini, M. et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23, 7436\u20137440 (2004).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR19","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1172\/JCI115743","volume":"89","author":"M Santoro","year":"1992","unstructured":"Santoro, M. et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 89, 1517\u20131522 (1992).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2011142_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1210\/endo.137.1.8536638","volume":"137","author":"SM Jhiang","year":"1996","unstructured":"Jhiang, S. M. et al. Targeted expression of the ret\/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137, 375\u2013378 (1996).","journal-title":"Endocrinology"},{"key":"BFnrendo2011142_CR21","first-page":"1821","volume":"12","author":"M Santoro","year":"1996","unstructured":"Santoro, M. et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET\/PTC1 oncogene in transgenic mice. Oncogene 12, 1821\u20131826 (1996).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR22","first-page":"5523","volume":"58","author":"DJ Powell Jr","year":"1998","unstructured":"Powell, D. J. Jr et al. The RET\/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 58, 5523\u20135528 (1998).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","volume":"60","author":"M Grieco","year":"1990","unstructured":"Grieco, M. et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60, 557\u2013563 (1990).","journal-title":"Cell"},{"key":"BFnrendo2011142_CR24","first-page":"509","volume":"9","author":"M Santoro","year":"1994","unstructured":"Santoro, M. et al. Molecular characterization of RET\/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 9, 509\u2013516 (1994).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR25","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1073\/pnas.89.5.1616","volume":"89","author":"MA Pierotti","year":"1992","unstructured":"Pierotti, M. A. et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET\/PTC. Proc. Natl Acad. Sci. USA 89, 1616\u20131620 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2011142_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/gcc.2870110108","volume":"11","author":"F Minoletti","year":"1994","unstructured":"Minoletti, F. et al. The two genes generating RET\/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes Cancer 11, 51\u201357 (1994).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrendo2011142_CR27","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1128\/MCB.13.1.358","volume":"13","author":"I Bongarzone","year":"1993","unstructured":"Bongarzone, I. et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol. Cell. Biol. 13, 358\u2013366 (1993).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrendo2011142_CR28","first-page":"198","volume":"58","author":"S Klugbauer","year":"1998","unstructured":"Klugbauer, S., Demidchik, E. P., Lengfelder, E. & Rabes, H. M. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res. 58, 198\u2013203 (1998).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR29","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1038\/sj.onc.1202824","volume":"18","author":"S Klugbauer","year":"1999","unstructured":"Klugbauer, S. & Rabes, H. M. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas. Oncogene 18, 4388\u20134393 (1999).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR30","first-page":"7028","volume":"60","author":"S Klugbauer","year":"2000","unstructured":"Klugbauer, S., Jauch, A., Lengfelder, E., Demidchik, E. & Rabes, H. M. A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8). Cancer Res. 60, 7028\u20137032 (2000).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR31","first-page":"2786","volume":"60","author":"K Salassidis","year":"2000","unstructured":"Salassidis, K. et al. Translocation t(10;14)(q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res. 60, 2786\u20132789 (2000).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR32","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1038\/sj.onc.1203772","volume":"19","author":"R Corvi","year":"2000","unstructured":"Corvi, R., Berger, N., Balczon, R. & Romeo, G. RET\/PCM-1: a novel fusion gene in papillary thyroid carcinoma. Oncogene 19, 4236\u20134242 (2000).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0027-5107(03)00056-3","volume":"527","author":"V Saenko","year":"2003","unstructured":"Saenko, V. et al. Novel tumorigenic rearrangement, Delta rfp\/ret, in a papillary thyroid carcinoma from externally irradiated patient. Mutat. Res. 527, 81\u201390 (2003).","journal-title":"Mutat. Res."},{"key":"BFnrendo2011142_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L","volume":"25","author":"T Nakata","year":"1999","unstructured":"Nakata, T. et al. Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma. Genes Chromosomes Cancer 25, 97\u2013103 (1999).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrendo2011142_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1677\/ERC-07-0039","volume":"14","author":"R Ciampi","year":"2007","unstructured":"Ciampi, R., Giordano, T. J., Wikenheiser-Brokamp, K., Koenig, R. J. & Nikiforov, Y. E. HOOK3-RET: a novel type of RET\/PTC rearrangement in papillary thyroid carcinoma. Endocr. Relat. Cancer 14, 445\u2013452 (2007).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrendo2011142_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1385\/EP:13:1:03","volume":"13","author":"YE Nikiforov","year":"2002","unstructured":"Nikiforov, Y. E. RET\/PTC rearrangement in thyroid tumors. Endocr. Pathol. 13, 3\u201316 (2002).","journal-title":"Endocr. Pathol."},{"key":"BFnrendo2011142_CR37","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00125480-200111000-00005","volume":"8","author":"G Tallini","year":"2001","unstructured":"Tallini, G. & Asa, S. L. RET oncogene activation in papillary thyroid carcinoma. Adv. Anat. Pathol. 8, 345\u2013354 (2001).","journal-title":"Adv. Anat. Pathol."},{"key":"BFnrendo2011142_CR38","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1210\/jc.2003-031870","volume":"89","author":"K Unger","year":"2004","unstructured":"Unger, K. et al. Heterogeneity in the distribution of RET\/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 89, 4272\u20134279 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR39","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1210\/jc.2006-1006","volume":"91","author":"Z Zhu","year":"2006","unstructured":"Zhu, Z., Ciampi, R., Nikiforova, M. N., Gandhi, M. & Nikiforov, Y. E. Prevalence of RET\/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J. Clin. Endocrinol. Metab. 91, 3603\u20133610 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/bjc.1993.370","volume":"68","author":"M Santoro","year":"1993","unstructured":"Santoro, M. et al. Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br. J. Cancer 68, 460\u2013464 (1993).","journal-title":"Br. J. Cancer"},{"key":"BFnrendo2011142_CR41","first-page":"287","volume":"4","author":"G Tallini","year":"1998","unstructured":"Tallini, G. et al. RET\/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 4, 287\u2013294 (1998).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2011142_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/106689690201000104","volume":"10","author":"MN Nikiforova","year":"2002","unstructured":"Nikiforova, M. N., Caudill, C. M., Biddinger, P. & Nikiforov, Y. E. Prevalence of RET\/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int. J. Surg. Pathol. 10, 15\u201322 (2002).","journal-title":"Int. J. Surg. Pathol."},{"key":"BFnrendo2011142_CR43","first-page":"1667","volume":"6","author":"Y Ishizaka","year":"1991","unstructured":"Ishizaka, Y. et al. Detection of retTPC\/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 6, 1667\u20131672 (1991).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00005537-199701000-00019","volume":"107","author":"A Wirtschafter","year":"1997","unstructured":"Wirtschafter, A. et al. Expression of the RET\/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 107, 95\u2013100 (1997).","journal-title":"Laryngoscope"},{"key":"BFnrendo2011142_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/106689690000800305","volume":"8","author":"OM Sheils","year":"2000","unstructured":"Sheils, O. M., O'Eary, J. J., Uhlmann, V., L\u00e4ttich, K. & Sweeney, E. C. ret\/PTC-1 Activation in Hashimoto Thyroiditis. Int. J. Surg. Pathol. 8, 185\u2013189 (2000).","journal-title":"Int. J. Surg. Pathol."},{"key":"BFnrendo2011142_CR46","first-page":"3211","volume":"86","author":"R Elisei","year":"2001","unstructured":"Elisei, R. et al. RET\/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 86, 3211\u20133216 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR47","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jcem.87.1.8180","volume":"87","author":"G Chiappetta","year":"2002","unstructured":"Chiappetta, G. et al. The RET\/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions. J. Clin. Endocrinol. Metab. 87, 364\u2013369 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR48","doi-asserted-by":"publisher","first-page":"E916","DOI":"10.1210\/jc.2010-1599","volume":"96","author":"MR Sapio","year":"2011","unstructured":"Sapio, M. R. et al. High growth rate of benign thyroid nodules bearing RET\/PTC rearrangements. J. Clin. Endocrinol. Metab. 96, E916\u2013E919 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1507\/endocrj.K10E-260","volume":"58","author":"A Guerra","year":"2011","unstructured":"Guerra, A. et al. Prevalence of RET\/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr. J. 58, 31\u201338 (2011).","journal-title":"Endocr. J."},{"key":"BFnrendo2011142_CR50","first-page":"2145","volume":"6","author":"P Radice","year":"1991","unstructured":"Radice, P. et al. The human tropomyosin gene involved in the generation of the TRK oncogene maps to chromosome 1q31. Oncogene 6, 2145\u20132148 (1991).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR51","first-page":"237","volume":"7","author":"A Greco","year":"1992","unstructured":"Greco, A. et al. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 7, 237\u2013242 (1992).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR52","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1006\/geno.1994.1566","volume":"23","author":"C Miranda","year":"1994","unstructured":"Miranda, C., Minoletti, F., Greco, A., Sozzi, G. & Pierotti, M. A. Refined localization of the human TPR gene to chromosome 1q25 by in situ hybridization. Genomics 23, 714\u2013715 (1994).","journal-title":"Genomics"},{"key":"BFnrendo2011142_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1098-2264(199605)16:1<1::AID-GCC1>3.0.CO;2-4","volume":"16","author":"MA Pierotti","year":"1996","unstructured":"Pierotti, M. A. et al. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer 16, 1\u201314 (1996).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrendo2011142_CR54","first-page":"223","volume":"4","author":"I Bongarzone","year":"1998","unstructured":"Bongarzone, I. et al. RET\/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin. Cancer Res. 4, 223\u2013228 (1998).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2011142_CR55","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1067\/msy.2000.110845","volume":"128","author":"TJ Musholt","year":"2000","unstructured":"Musholt, T. J. et al. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 128, 984\u2013993 (2000).","journal-title":"Surgery"},{"key":"BFnrendo2011142_CR56","first-page":"565","volume":"5","author":"HG Suarez","year":"1990","unstructured":"Suarez, H. G. et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5, 565\u2013570 (1990).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1046\/j.1365-2265.1999.00704.x","volume":"50","author":"CT Esapa","year":"1999","unstructured":"Esapa, C. T., Johnson, S. J., Kendall-Taylor, P., Lennard, T. W. & Harris, P. E. Prevalence of Ras mutations in thyroid neoplasia. Clin. Endocrinol. (Oxf.) 50, 529\u2013535 (1999).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2011142_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0344-0338(00)80015-1","volume":"196","author":"N Motoi","year":"2000","unstructured":"Motoi, N. et al. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol. Res. Pract. 196, 1\u20137 (2000).","journal-title":"Pathol. Res. Pract."},{"key":"BFnrendo2011142_CR59","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0959-8049(94)90130-9","volume":"30A","author":"G Manenti","year":"1994","unstructured":"Manenti, G., Pilotti, S., Re, F. C., Della Porta, G. & Pierotti, M. A. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur. J. Cancer 30A, 987\u2013993 (1994).","journal-title":"Eur. J. Cancer"},{"key":"BFnrendo2011142_CR60","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1210\/mend-4-10-1474","volume":"4","author":"H Namba","year":"1990","unstructured":"Namba, H., Rubin, S. A. & Fagin, J. A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 4, 1474\u20131479 (1990).","journal-title":"Mol. Endocrinol."},{"key":"BFnrendo2011142_CR61","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1210\/jcem-73-4-832","volume":"73","author":"H Karga","year":"1991","unstructured":"Karga, H. et al. Ras oncogene mutations in benign and malignant thyroid neoplasms. J. Clin. Endocrinol. Metab. 73, 832\u2013836 (1991).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR62","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1089\/thy.1996.6.409","volume":"6","author":"S Ezzat","year":"1996","unstructured":"Ezzat, S. et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6, 409\u2013416 (1996).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR63","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1309\/ND8D9LAJTRCTG6QD","volume":"120","author":"Z Zhu","year":"2003","unstructured":"Zhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H. & Nikiforov, Y. E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am. J. Clin. Pathol. 120, 71\u201377 (2003).","journal-title":"Am. J. Clin. Pathol."},{"key":"BFnrendo2011142_CR64","first-page":"903","volume":"16","author":"JA Fagin","year":"2002","unstructured":"Fagin, J. A. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol. Endocrinol. 16, 903\u2013911 (2002).","journal-title":"Mol. Endocrinol."},{"key":"BFnrendo2011142_CR65","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1038\/sj.onc.1203723","volume":"19","author":"HI Saavedra","year":"2000","unstructured":"Saavedra, H. I. et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 19, 3948\u20133954 (2000).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/thy.2000.10.19","volume":"10","author":"F Basolo","year":"2000","unstructured":"Basolo, F. et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10, 19\u201323 (2000).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR67","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1200\/JCO.2003.10.130","volume":"21","author":"G Garcia-Rostan","year":"2003","unstructured":"Garcia-Rostan, G. et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 21, 3226\u20133235 (2003).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2011142_CR68","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","volume":"95","author":"Y Cohen","year":"2003","unstructured":"Cohen, Y. et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst. 95, 625\u2013627 (2003).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrendo2011142_CR69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/path.1511","volume":"202","author":"V Trovisco","year":"2004","unstructured":"Trovisco, V. et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 202, 247\u2013251 (2004).","journal-title":"J. Pathol."},{"key":"BFnrendo2011142_CR70","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1365-2265.2005.02401.x","volume":"64","author":"C Carta","year":"2006","unstructured":"Carta, C. et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin. Endocrinol. (Oxf.) 64, 105\u2013109 (2006).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2011142_CR71","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4161\/cc.6.3.3818","volume":"6","author":"P Hou","year":"2007","unstructured":"Hou, P., Liu, D. & Xing, M. Functional characterization of the T1799\u20131801del and A1799\u20131816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 6, 377\u2013379 (2007).","journal-title":"Cell Cycle"},{"key":"BFnrendo2011142_CR72","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12022-009-9073-3","volume":"20","author":"S Chiosea","year":"2009","unstructured":"Chiosea, S. et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr. Pathol. 20, 122\u2013126 (2009).","journal-title":"Endocr. Pathol."},{"key":"BFnrendo2011142_CR73","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1210\/jc.2010-0337","volume":"95","author":"F Basolo","year":"2010","unstructured":"Basolo, F. et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab. 95, 4197\u20134205 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR74","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1172\/JCI23237","volume":"115","author":"R Ciampi","year":"2005","unstructured":"Ciampi, R. et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 115, 94\u2013101 (2005).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2011142_CR75","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"M Xing","year":"2005","unstructured":"Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245\u2013262 (2005).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrendo2011142_CR76","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1210\/jc.2003-030305","volume":"88","author":"H Namba","year":"2003","unstructured":"Namba, H. et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 88, 4393\u20134397 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR77","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1210\/jc.2003-030838","volume":"88","author":"MN Nikiforova","year":"2003","unstructured":"Nikiforova, M. N. et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 88, 5399\u20135404 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR78","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/modpathol.3800198","volume":"17","author":"S Begum","year":"2004","unstructured":"Begum, S. et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol. 17, 1359\u20131363 (2004).","journal-title":"Mod. Pathol."},{"key":"BFnrendo2011142_CR79","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","volume":"69","author":"JC Ricarte-Filho","year":"2009","unstructured":"Ricarte-Filho, J. C. et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885\u20134893 (2009).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR80","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1126\/science.289.5483.1357","volume":"289","author":"TG Kroll","year":"2000","unstructured":"Kroll, T. G. et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289, 1357\u20131360 (2000).","journal-title":"Science"},{"key":"BFnrendo2011142_CR81","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/sj.onc.1207399","volume":"23","author":"J Gregory Powell","year":"2004","unstructured":"Gregory Powell, J. et al. The PAX8\/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 23, 3634\u20133641 (2004).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR82","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0002-9440(10)63902-8","volume":"162","author":"CA French","year":"2003","unstructured":"French, C. A. et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am. J. Pathol. 162, 1053\u20131060 (2003).","journal-title":"Am. J. Pathol."},{"key":"BFnrendo2011142_CR83","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1210\/jc.2002-021907","volume":"88","author":"MN Nikiforova","year":"2003","unstructured":"Nikiforova, M. N. et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 88, 2318\u20132326 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR84","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1210\/jc.2002-021690","volume":"88","author":"T Dwight","year":"2003","unstructured":"Dwight, T. et al. Involvement of the PAX8\/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J. Clin. Endocrinol. Metab. 88, 4440\u20134445 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR85","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/00000478-200208000-00006","volume":"26","author":"MN Nikiforova","year":"2002","unstructured":"Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G. & Nikiforov, Y. E. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am. J. Surg. Pathol. 26, 1016\u20131023 (2002).","journal-title":"Am. J. Surg. Pathol."},{"key":"BFnrendo2011142_CR86","first-page":"3947","volume":"87","author":"AR Marques","year":"2002","unstructured":"Marques, A. R. et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab. 87, 3947\u20133952 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR87","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1210\/jc.2005-1336","volume":"91","author":"P Castro","year":"2006","unstructured":"Castro, P. et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 213\u2013220 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR88","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1172\/JCI116168","volume":"91","author":"JA Fagin","year":"1993","unstructured":"Fagin, J. A. et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 91, 179\u2013184 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2011142_CR89","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1172\/JCI116385","volume":"91","author":"R Donghi","year":"1993","unstructured":"Donghi, R. et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 91, 1753\u20131760 (1993).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo2011142_CR90","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/00019606-199403010-00003","volume":"3","author":"Y Dobashi","year":"1994","unstructured":"Dobashi, Y. et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn. Mol. Pathol. 3, 9\u201314 (1994).","journal-title":"Diagn. Mol. Pathol."},{"key":"BFnrendo2011142_CR91","first-page":"1369","volume":"52","author":"T Ito","year":"1992","unstructured":"Ito, T. et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res. 52, 1369\u20131371 (1992).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR92","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0002-9440(10)64045-X","volume":"158","author":"G Garcia-Rostan","year":"2001","unstructured":"Garcia-Rostan, G. et al. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 158, 987\u2013996 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrendo2011142_CR93","first-page":"1811","volume":"59","author":"G Garcia-Rostan","year":"1999","unstructured":"Garcia-Rostan, G. et al. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res. 59, 1811\u20131815 (1999).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR94","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1089\/thy.2004.14.1020","volume":"14","author":"T Kurihara","year":"2004","unstructured":"Kurihara, T. et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 14, 1020\u20131029 (2004).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR95","doi-asserted-by":"publisher","first-page":"10199","DOI":"10.1158\/0008-5472.CAN-04-4259","volume":"65","author":"G Garc\u00eda-Rost\u00e1n","year":"2005","unstructured":"Garc\u00eda-Rost\u00e1n, G. et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 65, 10199\u201310207 (2005).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR96","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1210\/jc.2007-1076","volume":"93","author":"L Santarpia","year":"2008","unstructured":"Santarpia, L., El-Naggar, A. K., Cote, G. J., Myers, J. N. & Sherman, S. I. Phosphatidylinositol 3-kinase\/akt and ras\/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 93, 278\u2013284 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR97","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-06-1125","volume":"13","author":"P Hou","year":"2007","unstructured":"Hou, P. et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase\/Akt pathway in thyroid cancer. Clin. Cancer Res. 13, 1161\u20131170 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2011142_CR98","first-page":"4710","volume":"57","author":"PL Dahia","year":"1997","unstructured":"Dahia, P. L. et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 57, 4710\u20134713 (1997).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR99","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/sj.bjc.6603455","volume":"95","author":"E Bonora","year":"2006","unstructured":"Bonora, E., Evangelisti, C., Bonichon, F., Tallini, G. & Romeo, G. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br. J. Cancer 95, 1529\u20131536 (2006).","journal-title":"Br. J. Cancer"},{"key":"BFnrendo2011142_CR100","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s004280000219","volume":"437","author":"V M\u00e1ximo","year":"2000","unstructured":"M\u00e1ximo, V. & Sobrinho-Sim\u00f5es, M. Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch. 437, 107\u2013115 (2000).","journal-title":"Virchows Arch."},{"key":"BFnrendo2011142_CR101","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s004280050209","volume":"433","author":"G Tallini","year":"1998","unstructured":"Tallini, G. Oncocytic tumours. Virchows Arch. 433, 5\u201312 (1998).","journal-title":"Virchows Arch."},{"key":"BFnrendo2011142_CR102","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/(SICI)1096-9896(1998110)186:3<292::AID-PATH190>3.0.CO;2-Y","volume":"186","author":"R Katoh","year":"1998","unstructured":"Katoh, R., Harach, H. R. & Williams, E. D. Solitary, multiple, and familial oxyphil tumours of the thyroid gland. J. Pathol. 186, 292\u2013299 (1998).","journal-title":"J. Pathol."},{"key":"BFnrendo2011142_CR103","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1038\/sj.bjc.6602547","volume":"92","author":"V M\u00e1ximo","year":"2005","unstructured":"M\u00e1ximo, V. et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br. J. Cancer 92, 1892\u20131898 (2005).","journal-title":"Br. J. Cancer"},{"key":"BFnrendo2011142_CR104","doi-asserted-by":"publisher","first-page":"33416","DOI":"10.1074\/jbc.M003929200","volume":"275","author":"JE Angell","year":"2000","unstructured":"Angell, J. E., Lindner, D. J., Shapiro, P. S., Hofmann, E. R. & Kalvakolanu, D. V. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J. Biol. Chem. 275, 33416\u201333426 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrendo2011142_CR105","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1073\/pnas.0703056104","volume":"104","author":"G Gasparre","year":"2007","unstructured":"Gasparre, G. et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc. Natl Acad. Sci. USA 104, 9001\u20139006 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2011142_CR106","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0002-9440(10)61132-7","volume":"160","author":"V M\u00e1ximo","year":"2002","unstructured":"M\u00e1ximo, V., Soares, P., Lima, J., Cameselle-Teijeiro, J. & Sobrinho-Sim\u00f5es, M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on H\u00fcrthle cell tumors. Am. J. Pathol. 160, 1857\u20131865 (2002).","journal-title":"Am. J. Pathol."},{"key":"BFnrendo2011142_CR107","doi-asserted-by":"publisher","first-page":"6087","DOI":"10.1158\/0008-5472.CAN-06-0171","volume":"66","author":"E Bonora","year":"2006","unstructured":"Bonora, E. et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res. 66, 6087\u20136096 (2006).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR108","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1038\/sj.onc.1208822","volume":"24","author":"TJ Giordano","year":"2005","unstructured":"Giordano, T. J. et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET\/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24, 6646\u20136656 (2005).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR109","doi-asserted-by":"publisher","first-page":"6586","DOI":"10.1158\/1078-0432.CCR-04-0053","volume":"10","author":"S Chevillard","year":"2004","unstructured":"Chevillard, S. et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin. Cancer Res. 10, 6586\u20136597 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2011142_CR110","doi-asserted-by":"publisher","first-page":"15044","DOI":"10.1073\/pnas.251547398","volume":"98","author":"Y Huang","year":"2001","unstructured":"Huang, Y. et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl Acad. Sci. USA 98, 15044\u201315049 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2011142_CR111","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1158\/0008-5472.CAN-03-3811","volume":"64","author":"C Mazzanti","year":"2004","unstructured":"Mazzanti, C. et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 64, 2898\u20132903 (2004).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR112","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.yasu.2005.04.009","volume":"39","author":"CC Lubitz","year":"2005","unstructured":"Lubitz, C. C. & Fahey, T. J. 3rd. The differentiation of benign and malignant thyroid nodules. Adv. Surg. 39, 355\u2013377 (2005).","journal-title":"Adv. Surg."},{"key":"BFnrendo2011142_CR113","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1158\/1078-0432.CCR-07-4495","volume":"14","author":"NB Prasad","year":"2008","unstructured":"Prasad, N. B. et al. Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin. Cancer Res. 14, 3327\u20133337 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2011142_CR114","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1210\/jc.2003-031811","volume":"89","author":"DJ Finley","year":"2004","unstructured":"Finley, D. J., Arora, N., Zhu, B., Gallagher, L. & Fahey, T. J. 3rd. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J. Clin. Endocrinol. Metab. 89, 3214\u20133223 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR115","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/onc.2011.44","volume":"30","author":"JA Knauf","year":"2011","unstructured":"Knauf, J. A. et al. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30, 3153\u20133162 (2011).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR116","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1073\/pnas.0610733104","volume":"104","author":"V Vasko","year":"2007","unstructured":"Vasko, V. et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc. Natl Acad. Sci. USA 104, 2803\u20132808 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2011142_CR117","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/modpathol.2008.105","volume":"21","author":"YT Chen","year":"2008","unstructured":"Chen, Y. T., Kitabayashi, N., Zhou, X. K., Fahey, T. J. 3rd & Scognamiglio, T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol. 21, 1139\u20131146 (2008).","journal-title":"Mod. Pathol."},{"key":"BFnrendo2011142_CR118","doi-asserted-by":"publisher","first-page":"19075","DOI":"10.1073\/pnas.0509603102","volume":"102","author":"H He","year":"2005","unstructured":"He, H. et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA 102, 19075\u201319080 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrendo2011142_CR119","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12022-009-9069-z","volume":"20","author":"MN Nikiforova","year":"2009","unstructured":"Nikiforova, M. N., Chiosea, S. I. & Nikiforov, Y. E. MicroRNA expression profiles in thyroid tumors. Endocr. Pathol. 20, 85\u201391 (2009).","journal-title":"Endocr. Pathol."},{"key":"BFnrendo2011142_CR120","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1677\/erc.1.01209","volume":"13","author":"P Pallante","year":"2006","unstructured":"Pallante, P. et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13, 497\u2013508 (2006).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrendo2011142_CR121","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1210\/jc.2007-2696","volume":"93","author":"MN Nikiforova","year":"2008","unstructured":"Nikiforova, M. N., Tseng, G. C., Steward, D., Diorio, D. & Nikiforov, Y. E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 93, 1600\u20131608 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR122","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1677\/ERC-07-0129","volume":"14","author":"R Visone","year":"2007","unstructured":"Visone, R. et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer 14, 791\u2013798 (2007).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrendo2011142_CR123","doi-asserted-by":"publisher","first-page":"E546","DOI":"10.1210\/jc.2010-1594","volume":"96","author":"K Jazdzewski","year":"2011","unstructured":"Jazdzewski, K. et al. Thyroid hormone receptor beta (THRB) is a major target gene for microRNAs deregulated in papillary thyroid carcinoma (PTC). J. Clin. Endocrinol. Metab. 96, E546\u2013E553 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR124","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1210\/jc.2006-0693","volume":"91","author":"F Weber","year":"2006","unstructured":"Weber, F., Teresi, R. E., Broelsch, C. E., Frilling, A. & Eng, C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 3584\u20133591 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR125","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1038\/sj.onc.1210564","volume":"26","author":"R Visone","year":"2007","unstructured":"Visone, R. et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26, 7590\u20137595 (2007).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR126","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1210\/en.2006-0927","volume":"148","author":"M Xing","year":"2007","unstructured":"Xing, M. Gene methylation in thyroid tumorigenesis. Endocrinology 148, 948\u2013953 (2007).","journal-title":"Endocrinology"},{"key":"BFnrendo2011142_CR127","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/0008-5472.CAN-09-2812","volume":"70","author":"H Zuo","year":"2010","unstructured":"Zuo, H. et al. Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 70, 1389\u20131397 (2010).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR128","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1530\/JME-10-0150","volume":"46","author":"D Russo","year":"2011","unstructured":"Russo, D., Damante, G., Puxeddu, E., Durante, C. & Filetti, S. Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endocrinol. 46, R73\u2013R81 (2011).","journal-title":"J. Mol. Endocrinol."},{"key":"BFnrendo2011142_CR129","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1002\/ijc.22110","volume":"119","author":"S Hu","year":"2006","unstructured":"Hu, S. et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int. J. Cancer 119, 2322\u20132329 (2006).","journal-title":"Int. J. Cancer"},{"key":"BFnrendo2011142_CR130","first-page":"1093","volume":"6","author":"HM Rabes","year":"2000","unstructured":"Rabes, H. M. et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res. 6, 1093\u20131103 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2011142_CR131","first-page":"1690","volume":"57","author":"YE Nikiforov","year":"1997","unstructured":"Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Munoz, H. & Fagin, J. A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 57, 1690\u20131694 (1997).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR132","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/sj.onc.1200206","volume":"15","author":"A Bounacer","year":"1997","unstructured":"Bounacer, A. et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15, 1263\u20131273 (1997).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR133","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.0.CO;2-L","volume":"80","author":"J Smida","year":"1999","unstructured":"Smida, J. et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int. J. Cancer 80, 32\u201338 (1999).","journal-title":"Int. J. Cancer"},{"key":"BFnrendo2011142_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2003.12.004","volume":"209","author":"MN Nikiforova","year":"2004","unstructured":"Nikiforova, M. N. et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett. 209, 1\u20136 (2004).","journal-title":"Cancer Lett."},{"key":"BFnrendo2011142_CR135","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-08-0293","volume":"68","author":"K Hamatani","year":"2008","unstructured":"Hamatani, K. et al. RET\/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res. 68, 7176\u20137182 (2008).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR136","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mc.20277","volume":"46","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol. Carcinog. 46, 242\u2013248 (2007).","journal-title":"Mol. Carcinog."},{"key":"BFnrendo2011142_CR137","first-page":"2940","volume":"53","author":"T Ito","year":"1993","unstructured":"Ito, T. et al. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res. 53, 2940\u20132943 (1993).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR138","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1210\/jc.2004-1811","volume":"90","author":"CM Caudill","year":"2005","unstructured":"Caudill, C. M., Zhu, Z., Ciampi, R., Stringer, J. R. & Nikiforov, Y. E. Dose-dependent generation of RET\/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J. Clin. Endocrinol. Metab. 90, 2364\u20132369 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR139","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/sj.onc.1201313","volume":"15","author":"T Mizuno","year":"1997","unstructured":"Mizuno, T., Kyoizumi, S., Suzuki, T., Iwamoto, K. S. & Seyama, T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 15, 1455\u20131460 (1997).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR140","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/sj.onc.1203343","volume":"19","author":"T Mizuno","year":"2000","unstructured":"Mizuno, T. et al. Preferential induction of RET\/PTC1 rearrangement by X-ray irradiation. Oncogene 19, 438\u2013443 (2000).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR141","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1126\/science.290.5489.138","volume":"290","author":"MN Nikiforova","year":"2000","unstructured":"Nikiforova, M. N. et al. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 290, 138\u2013141 (2000).","journal-title":"Science"},{"key":"BFnrendo2011142_CR142","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1038\/sj.onc.1209268","volume":"25","author":"M Gandhi","year":"2006","unstructured":"Gandhi, M., Medvedovic, M., Stringer, J. R. & Nikiforov, Y. E. Interphase chromosome folding determines spatial proximity of genes participating in carcinogenic RET\/PTC rearrangements. Oncogene 25, 2360\u20132366 (2006).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR143","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1158\/0008-5472.CAN-04-4294","volume":"65","author":"E Roccato","year":"2005","unstructured":"Roccato, E. et al. Proximity of TPR and NTRK1 rearranging loci in human thyrocytes. Cancer Res. 65, 2572\u20132576 (2005).","journal-title":"Cancer Res."},{"key":"BFnrendo2011142_CR144","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1196\/annals.1322.002","volume":"1028","author":"I B\u00fcttel","year":"2004","unstructured":"B\u00fcttel, I., Fechter, A. & Schwab, M. Common fragile sites and cancer: targeted cloning by insertional mutagenesis. Ann. NY Acad. Sci. 1028, 14\u201327 (2004).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrendo2011142_CR145","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0168-9525(01)02303-4","volume":"17","author":"RI Richards","year":"2001","unstructured":"Richards, R. I. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 17, 339\u2013345 (2001).","journal-title":"Trends Genet."},{"key":"BFnrendo2011142_CR146","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1038\/onc.2009.502","volume":"29","author":"M Gandhi","year":"2010","unstructured":"Gandhi, M., Dillon, L. W., Pramanik, S., Nikiforov, Y. E. & Wang, Y. H. DNA breaks at fragile sites generate oncogenic RET\/PTC rearrangements in human thyroid cells. Oncogene 29, 2272\u20132280 (2010).","journal-title":"Oncogene"},{"key":"BFnrendo2011142_CR147","first-page":"1170","volume":"85","author":"CL Fenton","year":"2000","unstructured":"Fenton, C. L. et al. The ret\/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. J. Clin. Endocrinol. Metab. 85, 1170\u20131175 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR148","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1210\/jc.2008-2390","volume":"94","author":"H Guan","year":"2009","unstructured":"Guan, H. et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 94, 1612\u20131617 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR149","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1089\/thy.1998.8.1179","volume":"8","author":"P Lind","year":"1998","unstructured":"Lind, P. et al. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 8, 1179\u20131183 (1998).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR150","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/jnci\/djp354","volume":"101","author":"G Pellegriti","year":"2009","unstructured":"Pellegriti, G. et al. Papillary thyroid cancer incidence in the volcanic area of Sicily. J. Natl Cancer Inst. 101, 1575\u20131583 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrendo2011142_CR151","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","volume":"55","author":"DM Parkin","year":"2005","unstructured":"Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74\u2013108 (2005).","journal-title":"CA Cancer J. Clin."},{"key":"BFnrendo2011142_CR152","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/dc.10043","volume":"26","author":"ZW Baloch","year":"2002","unstructured":"Baloch, Z. W., Fleisher, S., LiVolsi, V. A. & Gupta, P. K. Diagnosis of \u201cfollicular neoplasm\u201d: a gray zone in thyroid fine-needle aspiration cytology. Diagn. Cytopathol. 26, 41\u201344 (2002).","journal-title":"Diagn. Cytopathol."},{"key":"BFnrendo2011142_CR153","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1056\/NEJM199302253280807","volume":"328","author":"EL Mazzaferri","year":"1993","unstructured":"Mazzaferri, E. L. Management of a solitary thyroid nodule. N. Engl. J. Med. 328, 553\u2013559 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo2011142_CR154","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/dc.20830","volume":"36","author":"ZW Baloch","year":"2008","unstructured":"Baloch, Z. W. et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn. Cytopathol. 36, 425\u2013437 (2008).","journal-title":"Diagn. Cytopathol."},{"key":"BFnrendo2011142_CR155","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1089\/thy.2009.0240","volume":"19","author":"MN Nikiforova","year":"2009","unstructured":"Nikiforova, M. N. & Nikiforov, Y. E. Molecular diagnostics and predictors in thyroid cancer. Thyroid 19, 1351\u20131361 (2009).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR156","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1210\/jc.2010-1082","volume":"96","author":"SK Kim","year":"2011","unstructured":"Kim, S. K. et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J. Clin. Endocrinol. Metab. 96, 658\u2013664 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR157","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1210\/jc.2009-2795","volume":"95","author":"SW Kim","year":"2010","unstructured":"Kim, S. W. et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J. Clin. Endocrinol. Metab. 95, 3693\u20133700 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR158","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/thy.2009.0226","volume":"20","author":"SY Nam","year":"2010","unstructured":"Nam, S. Y. et al. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis. Thyroid 20, 273\u2013279 (2010).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR159","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1210\/jc.2009-0247","volume":"94","author":"YE Nikiforov","year":"2009","unstructured":"Nikiforov, Y. E. et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab. 94, 2092\u20132098 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR160","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1089\/thy.2007.0008","volume":"17","author":"G Pizzolanti","year":"2007","unstructured":"Pizzolanti, G. et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET\/PTC rearrangement. Thyroid 17, 1109\u20131115 (2007).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR161","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1365-2265.2008.03293.x","volume":"70","author":"YS Jo","year":"2009","unstructured":"Jo, Y. S. et al. Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin. Endocrinol. (Oxf.) 70, 139\u2013144 (2009).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2011142_CR162","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1158\/1078-0432.CCR-03-0273","volume":"10","author":"Y Cohen","year":"2004","unstructured":"Cohen, Y. et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin. Cancer Res. 10, 2761\u20132765 (2004).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo2011142_CR163","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1210\/jc.2003-032221","volume":"89","author":"G Salvatore","year":"2004","unstructured":"Salvatore, G. et al. Analysis of BRAF point mutation and RET\/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 89, 5175\u20135180 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR164","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/PDM.0b013e31815d059d","volume":"17","author":"SK Kim","year":"2008","unstructured":"Kim, S. K. et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn. Mol. Pathol. 17, 118\u2013125 (2008).","journal-title":"Diagn. Mol. Pathol."},{"key":"BFnrendo2011142_CR165","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1210\/jc.2009-2103","volume":"95","author":"S Cantara","year":"2010","unstructured":"Cantara, S. et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J. Clin. Endocrinol. Metab. 95, 1365\u20131369 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR166","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/cncy.20063","volume":"118","author":"NP Ohori","year":"2010","unstructured":"Ohori, N. P. et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of \u201cfollicular lesion of undetermined significance\/atypia of undetermined significance\u201d. Cancer Cytopathol. 118, 17\u201323 (2010).","journal-title":"Cancer Cytopathol."},{"key":"BFnrendo2011142_CR167","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00268-010-0720-0","volume":"34","author":"W Moses","year":"2010","unstructured":"Moses, W. et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J. Surg. 34, 2589\u20132594 (2010).","journal-title":"World J. Surg."},{"key":"BFnrendo2011142_CR168","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-6614-4-5","volume":"4","author":"A Cyniak-Magierska","year":"2011","unstructured":"Cyniak-Magierska, A., Wojciechowska-Durczynska, K., Krawczyk-Rusiecka, K., Zygmunt, A. & Lewinski, A. Assessment of RET\/PTC1 and RET\/PTC3 rearrangements in fine-needle aspiration biopsy specimens collected from patients with Hashimoto's thyroiditis. Thyroid Res. 4, 5 (2011).","journal-title":"Thyroid Res."},{"key":"BFnrendo2011142_CR169","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-87666-5","volume-title":"The Bethesda System for Reporting Thyroid Cytopathology","author":"SZ Ali","year":"2010","unstructured":"Ali, S. Z. & Cibas, E. S. (Eds) The Bethesda System for Reporting Thyroid Cytopathology (Springer, New York, 2010)."},{"key":"BFnrendo2011142_CR170","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167\u20131214 (2009).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR171","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1210\/er.2007-0007","volume":"28","author":"M Xing","year":"2007","unstructured":"Xing, M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 28, 742\u2013762 (2007).","journal-title":"Endocr. Rev."},{"key":"BFnrendo2011142_CR172","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"M Xing","year":"2005","unstructured":"Xing, M. et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90, 6373\u20136379 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR173","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2265.2006.02605.x","volume":"65","author":"TY Kim","year":"2006","unstructured":"Kim, T. Y. et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 65, 364\u2013368 (2006).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo2011142_CR174","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/SLA.0b013e318148563d","volume":"246","author":"E Kebebew","year":"2007","unstructured":"Kebebew, E. et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann. Surg. 246, 466\u2013470 (2007).","journal-title":"Ann. Surg."},{"key":"BFnrendo2011142_CR175","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1200\/JCO.2008.20.1426","volume":"27","author":"M Xing","year":"2009","unstructured":"Xing, M. et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 27, 2977\u20132982 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrendo2011142_CR176","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1210\/jc.2008-0607","volume":"93","author":"R Elisei","year":"2008","unstructured":"Elisei, R. et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab. 93, 3943\u20133949 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR177","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.surg.2010.09.005","volume":"148","author":"CJ O'Neill","year":"2010","unstructured":"O'Neill, C. J. et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148, 1139\u20131145 (2010).","journal-title":"Surgery"},{"key":"BFnrendo2011142_CR178","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.surg.2009.09.011","volume":"146","author":"L Yip","year":"2009","unstructured":"Yip, L. et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 146, 1215\u20131223 (2009).","journal-title":"Surgery"},{"key":"BFnrendo2011142_CR179","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","volume":"13","author":"G Riesco-Eizaguirre","year":"2006","unstructured":"Riesco-Eizaguirre, G., Guti\u00e9rrez-Mart\u00ednez, P., Garc\u00eda-Cabezas, M. A., Nistal, M. & Santisteban, P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I\u2013 targeting to the membrane. Endocr. Relat. Cancer 13, 257\u2013269 (2006).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrendo2011142_CR180","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1210\/jc.2006-2707","volume":"92","author":"C Durante","year":"2007","unstructured":"Durante, C. et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92, 2840\u20132843 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR181","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mce.2009.10.012","volume":"321","author":"M Xing","year":"2010","unstructured":"Xing, M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol. Cell. Endocrinol. 321, 86\u201393 (2010).","journal-title":"Mol. Cell. Endocrinol."},{"key":"BFnrendo2011142_CR182","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/cncr.22912","volume":"110","author":"V Rodolico","year":"2007","unstructured":"Rodolico, V. et al. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid \u22641 cm and their paired lymph node metastases. Cancer 110, 1218\u20131226 (2007).","journal-title":"Cancer"},{"key":"BFnrendo2011142_CR183","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1245\/s10434-008-0233-3","volume":"16","author":"X Lee","year":"2009","unstructured":"Lee, X. et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann. Surg. Oncol. 16, 240\u2013245 (2009).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrendo2011142_CR184","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1210\/jc.2007-1179","volume":"92","author":"C Lupi","year":"2007","unstructured":"Lupi, C. et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 92, 4085\u20134090 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR185","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1677\/ERC-07-0212","volume":"15","author":"F Frasca","year":"2008","unstructured":"Frasca, F. et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr. Relat. Cancer 15, 191\u2013205 (2008).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrendo2011142_CR186","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1148\/radiol.2533090471","volume":"253","author":"JY Kwak","year":"2009","unstructured":"Kwak, J. Y. et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253, 854\u2013860 (2009).","journal-title":"Radiology"},{"key":"BFnrendo2011142_CR187","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1245\/s10434-010-1129-6","volume":"17","author":"KL Lin","year":"2010","unstructured":"Lin, K. L. et al. The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann. Surg. Oncol. 17, 3294\u20133300 (2010).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrendo2011142_CR188","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrendo.2010.213","volume":"7","author":"P Soares","year":"2011","unstructured":"Soares, P. & Sobrinho-Sim\u00f5es, M. Cancer: Small papillary thyroid cancers\u2014is BRAF of prognostic value? Nat. Rev. Endocrinol. 7, 9\u201310 (2011).","journal-title":"Nat. Rev. Endocrinol."},{"key":"BFnrendo2011142_CR189","doi-asserted-by":"crossref","unstructured":"Howell, G. M. et al. Both BRAF V600E mutation and older age (\u226565 years) are associated with recurrent papillary thyroid cancer. Ann. Surg. Oncol. doi: 10.1245\/s10434-011-1781-5.","DOI":"10.1245\/s10434-011-1781-5"},{"key":"BFnrendo2011142_CR190","unstructured":"Niemeier, L. A. et al. A combined molecular-pathological score improves risk stratification of thyroid papillary microcarcinoma. Cancer (in press)."},{"key":"BFnrendo2011142_CR191","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/gcc.20505","volume":"47","author":"G Belge","year":"2008","unstructured":"Belge, G. et al. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias. Genes Chromosomes Cancer 47, 656\u2013663 (2008).","journal-title":"Genes Chromosomes Cancer"},{"key":"BFnrendo2011142_CR192","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ejca.2008.02.039","volume":"44","author":"G Chiappetta","year":"2008","unstructured":"Chiappetta, G. et al. HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur. J. Cancer 44, 1015\u20131021 (2008).","journal-title":"Eur. J. Cancer"},{"key":"BFnrendo2011142_CR193","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cncy.20095","volume":"118","author":"PJ Lappinga","year":"2010","unstructured":"Lappinga, P. J. et al. HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol. 118, 287\u2013297 (2010).","journal-title":"Cancer Cytopathol."},{"key":"BFnrendo2011142_CR194","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.surg.2010.09.025","volume":"148","author":"A Mathur","year":"2010","unstructured":"Mathur, A. et al. A prospective study evaluating the accuracy of using combined clinical factors and candidate diagnostic markers to refine the accuracy of thyroid fine needle aspiration biopsy. Surgery 148, 1170\u20131176 (2010).","journal-title":"Surgery"},{"key":"BFnrendo2011142_CR195","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1210\/jc.2010-1087","volume":"95","author":"D Chudova","year":"2010","unstructured":"Chudova, D. et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J. Clin. Endocrinol. Metab. 95, 5296\u20135304 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo2011142_CR196","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/thy.2010.0356","volume":"21","author":"H Mazeh","year":"2011","unstructured":"Mazeh, H. et al. Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 21, 111\u2013118 (2011).","journal-title":"Thyroid"},{"key":"BFnrendo2011142_CR197","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1245\/s10434-011-1733-0","volume":"18","author":"L Yip","year":"2011","unstructured":"Yip, L. et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol. 18, 2035\u20132041 (2011).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrendo2011142_CR198","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1089\/thy.2009.0027","volume":"20","author":"CK Chou","year":"2010","unstructured":"Chou, C. K. et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Thyroid 20, 489\u2013494 (2010).","journal-title":"Thyroid"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2011.142","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2011.142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2011.142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:33:06Z","timestamp":1712773986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2011.142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,30]]},"references-count":198,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["BFnrendo2011142"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2011.142","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,30]]}}}